Serigne Lo (@SerineLo) profile picture
Joined June 2016
Photo by Serigne Lo (@SerineLo)
Thrilled to celebrate three outstanding colleagues at @MelanomaAus! Huge congratulations to Professor Alex Menzies, Professor Sydney Ch’ng and Professor Serigne Lo on their well-deserved promotions to Professor at @sydney_uni. All exceptional researchers who are making a real difference in #melanoma research. @SerineLo #AlexMenzies @drsydneychng @Science_Academy @FulbrightAUS @AAHMS_health @ausoftheyear
We're very pleased and proud to announce that three Associate Professors from our Melanoma Institute Australia faculty have been promoted to Professor by @Sydney_Uni in recognition of their outstanding contribution to #melanoma research. Congratulations Professor Alex Menzies, Professor Sydney Ch'ng and Professor Serigne Lo! #Professor @syd_health #AlexMenzies @drsydneychng @SerineLo
2
11
1,443
Risk of melanoma-related death increased significantly for patients with primary tumors of 0.8 to 1.0 mm in thickness. ja.ma/41oINXq
1
5
838
A/Prof @SerineLo leads a team responsible for the design & analysis of clinical trials, and the development of tools that guide the treatment of melanoma patients. You can deep-dive into his life and research in our latest #LabLife blog > bit.ly/4dXZrjT #melanoma
1
12
406
Today MIA launched a world-first online calculator, the #ImmunotherapyOutcomesPrediction tool, to predict an advanced melanoma patient’s response to immunotherapy. A vital advance in personalising cancer treatment. @gabyrogers shared the story on #9News. @inespiresilva @amenzies9
Melanoma patients whose tumours have spread, can now find out if immunotherapy will work for them, BEFORE the treatment even begins. In a world first, an Australian-developed calculator can predict a patient's response, so that precious time isn't lost. @gabyrogers #9News
5
9
MIA's new #ImmunotherapyOutcomesPrediction online calculator, allows oncologists to assess patient's response to immunotherapy & plan personalised treatment. Saving lives, & reducing physical, emotional & financial burden. @TomHartley_7 #7NEWS @syd_health https://teapawt.org/t.co/nzJPwqOB2T
New Australian technology is offering melanoma patients something they've never had before. A tool to predict the efficacy of treatments giving more personalised care, and a better chance of survival. youtu.be/oCDSoCUT_ns #Melanoma #7NEWS
3
5
Proud of MIA researcher @_graceattrill, lead author on this paper published in #JITC. A significant discovery by the MIA team in our quest to improve outcomes for immunotherapy-treated patients. @JWilmott38 #immunotherapy
New #JITC article: Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy https://teapawt.org/t.co/N13Qh73f3D @_graceattrill @palendira @ProfRScolyerMIA @ProfGLongMIA @JWilmott38
1
11
Serigne Lo: the man defining the new speciality of “Statistical oncology”! ⁦⁩The man that creates all the magic for the colleagues ⁦@ProfGLongMIA, Alex van Akkooi and colleagues at ⁦@MelanomaAus⁩ Glad to meet him at #ASCO22
3
14
Congrats to @AnneECust , @SerineLo and @AlexVarey & their teams for bringing the MIA Melanoma Risk Calculators to realisation. Have you checked your melanoma risk? melanomarisk.org.au
3
9
#melanoma doesn’t stop in a pandemic- use our @MelanomaAus online calculators at melanomarisk.org.au to calculate your individual risk- prevention & early detection key to saving lives! @ProfGLongMIA @AnneECust @AlexVarey @SerineLo
A series of online tools have been launched to help prevent skin cancer in our sunburnt country. | @alicemhogg
5
1
12
Below is 1st of series of publictns from outstanding @MelanomaAus visiting Dutch dermatologist scholar MaryAnn El Sharouni: Predicting recurrence in pts with sentinel node‐neg #melanoma: validation of EORTC nomogram using population‐based data bjssjournals.onlinelibrary.w… @SerineLo
3
3